AR069030A1 - Derivados de 1,2,4-triazol amino y de isoxazoles, composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento de trastornos gastrointestinales y del snc - Google Patents
Derivados de 1,2,4-triazol amino y de isoxazoles, composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento de trastornos gastrointestinales y del sncInfo
- Publication number
- AR069030A1 AR069030A1 ARP080104651A ARP080104651A AR069030A1 AR 069030 A1 AR069030 A1 AR 069030A1 AR P080104651 A ARP080104651 A AR P080104651A AR P080104651 A ARP080104651 A AR P080104651A AR 069030 A1 AR069030 A1 AR 069030A1
- Authority
- AR
- Argentina
- Prior art keywords
- oxy
- alkyl
- silyl
- tert
- dimethyl
- Prior art date
Links
- -1 OF 1,2,4-TRIAZOL AMINO Chemical class 0.000 title abstract 2
- 208000018522 Gastrointestinal disease Diseases 0.000 title 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 3
- 125000001153 fluoro group Chemical group F* 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 abstract 2
- PAYRFTHZTMFSJQ-UHFFFAOYSA-N 2-[tert-butyl(dimethyl)silyl]oxyacetamide Chemical compound CC(C)(C)[Si](C)(C)OCC(N)=O PAYRFTHZTMFSJQ-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los siguientes intermediarios de síntesis: 2-{[tert-butil(dimetil)silil]oxi}acetamida; [tert-butil(dimetil)silil]oxi}acetonitrilo; (1Z)-2-{[tert-butil(dimetil)silil]oxi}-N'-hidroxietanimidamida; y (1Z)-2-{[tert-butil(dimetil)silil]oxi}-N'-{[(3-metilfenil)carbonil]oxi}etanimidamida. Reivindicación 1: Un compuesto de la fórmula (1) donde: X es un resto del grupo de fórmulas (2); R¹ es metil halógeno o ciano; R² es hidrógeno o fluoro; R³ es alquil C₁₋₃ o ciclopropil; R⁴ es alquil C₁₋₃ o ciclopropil; R⁵ es hidrógeno, alquil C₁₋₃ o ciclopropil; Z es un resto del grupo de fórmulas (3) donde R⁶ es hidrógeno, fluoro, alquil C₁₋₃ o alcoxi C₁₋₃; R⁷ es hidrógeno, fluoro, alquil C₁₋₃ o alcoxi C₁₋₃; así como sales, hidratos, isoformas, tautómeros y/o enantiómeros del mismo farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98295607P | 2007-10-26 | 2007-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069030A1 true AR069030A1 (es) | 2009-12-23 |
Family
ID=40579779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104651A AR069030A1 (es) | 2007-10-26 | 2008-10-24 | Derivados de 1,2,4-triazol amino y de isoxazoles, composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento de trastornos gastrointestinales y del snc |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20090111821A1 (es) |
| EP (1) | EP2212316A4 (es) |
| JP (1) | JP2011500798A (es) |
| KR (1) | KR20100089091A (es) |
| CN (1) | CN101918399A (es) |
| AR (1) | AR069030A1 (es) |
| AU (1) | AU2008317544A1 (es) |
| BR (1) | BRPI0818679A2 (es) |
| CA (1) | CA2702974A1 (es) |
| CL (1) | CL2008003182A1 (es) |
| CR (1) | CR11391A (es) |
| DO (1) | DOP2010000124A (es) |
| EA (1) | EA201000656A1 (es) |
| IL (1) | IL205289A0 (es) |
| MX (1) | MX2010004362A (es) |
| NI (1) | NI201000072A (es) |
| PE (1) | PE20091348A1 (es) |
| TW (1) | TW200922585A (es) |
| UY (1) | UY31427A1 (es) |
| WO (1) | WO2009054794A1 (es) |
| ZA (1) | ZA201002854B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010255552A1 (en) * | 2009-06-05 | 2012-01-12 | Oslo University Hospital Hf | Azole derivatives as Wtn pathway inhibitors |
| CA2820800A1 (en) | 2010-12-08 | 2012-06-14 | Oslo University Hospital Hf | Triazole derivatives as wnt signaling pathway inhibitors |
| RU2495687C1 (ru) * | 2012-06-19 | 2013-10-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Минздравсоцразвития Российской Федерации | Способ лечения больных гастроэзофагеальной рефлюксной болезнью |
| UA113223C2 (xx) * | 2012-08-13 | 2016-12-26 | Арилетинілпіримідини | |
| EP2857387A1 (en) | 2013-10-07 | 2015-04-08 | Boehringer Ingelheim International Gmbh | Process for manufacturing 1,6-dihydro-6-oxo-4-pyridazine carboxylic acid |
| US9745308B2 (en) | 2014-09-12 | 2017-08-29 | Chiesi Farmaceutici S.P.A. | Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors |
| CA3075727A1 (en) | 2017-09-18 | 2019-03-21 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9420355D0 (en) * | 1994-10-10 | 1994-11-23 | Univ Nottingham | Preparation of protein microspheres, films and coatings |
| JP4060884B2 (ja) * | 1995-08-28 | 2008-03-12 | 昭和薬品化工株式会社 | 局所麻酔用組成物 |
| US5962536A (en) * | 1998-07-31 | 1999-10-05 | Komer; Gene | Injectable propofol formulations |
| WO2005077345A1 (en) * | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| RU2006127575A (ru) * | 2004-02-18 | 2008-03-27 | Астразенека Аб (Se) | Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата |
| BRPI0507498A (pt) * | 2004-02-18 | 2007-07-10 | Astrazeneca Ab | composto, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir ativação de receptores de mglur 5 |
| AR058807A1 (es) * | 2005-09-29 | 2008-02-27 | Astrazeneca Ab | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 |
| US20070197532A1 (en) * | 2005-11-18 | 2007-08-23 | Cao Sheldon X | Glucokinase activators |
| MY146537A (en) * | 2006-03-24 | 2012-08-15 | Eisai R&D Man Co Ltd | Triazolone derivative |
| TW200808777A (en) * | 2006-05-05 | 2008-02-16 | Astrazeneca Ab | MGLUR5 modulators III |
| TW200811156A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators IV |
| TW200811179A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators VI |
| TW200811157A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
| TW200811137A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators II |
| TW200808800A (en) * | 2006-05-05 | 2008-02-16 | Astrazeneca Ab | MGluR5 modulators V |
| TW200821305A (en) * | 2006-10-05 | 2008-05-16 | Astrazeneca Ab | MGluR5 modulators |
| EP2250165B1 (en) * | 2007-12-21 | 2018-07-25 | Merck Serono S.A. | Triazole oxadiazoles derivatives |
| US20110039695A1 (en) * | 2008-04-10 | 2011-02-17 | Basf Se | Substituted Pyridazinylmethyl Sulfonamides |
-
2008
- 2008-10-23 JP JP2010530962A patent/JP2011500798A/ja active Pending
- 2008-10-23 EA EA201000656A patent/EA201000656A1/ru unknown
- 2008-10-23 WO PCT/SE2008/051197 patent/WO2009054794A1/en not_active Ceased
- 2008-10-23 CN CN2008801236495A patent/CN101918399A/zh active Pending
- 2008-10-23 EP EP08842741A patent/EP2212316A4/en not_active Withdrawn
- 2008-10-23 TW TW097140705A patent/TW200922585A/zh unknown
- 2008-10-23 MX MX2010004362A patent/MX2010004362A/es unknown
- 2008-10-23 BR BRPI0818679 patent/BRPI0818679A2/pt not_active Application Discontinuation
- 2008-10-23 CA CA2702974A patent/CA2702974A1/en not_active Abandoned
- 2008-10-23 KR KR1020107011336A patent/KR20100089091A/ko not_active Withdrawn
- 2008-10-23 AU AU2008317544A patent/AU2008317544A1/en not_active Abandoned
- 2008-10-24 AR ARP080104651A patent/AR069030A1/es unknown
- 2008-10-24 US US12/258,114 patent/US20090111821A1/en not_active Abandoned
- 2008-10-24 CL CL2008003182A patent/CL2008003182A1/es unknown
- 2008-10-24 UY UY31427A patent/UY31427A1/es not_active Application Discontinuation
- 2008-10-24 PE PE2008001830A patent/PE20091348A1/es not_active Application Discontinuation
-
2010
- 2010-04-22 ZA ZA2010/02854A patent/ZA201002854B/en unknown
- 2010-04-22 IL IL205289A patent/IL205289A0/en unknown
- 2010-04-26 DO DO2010000124A patent/DOP2010000124A/es unknown
- 2010-04-26 NI NI201000072A patent/NI201000072A/es unknown
- 2010-04-26 CR CR11391A patent/CR11391A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20091348A1 (es) | 2009-10-04 |
| UY31427A1 (es) | 2009-05-29 |
| ZA201002854B (en) | 2011-10-26 |
| BRPI0818679A2 (pt) | 2015-04-14 |
| CL2008003182A1 (es) | 2009-11-27 |
| CA2702974A1 (en) | 2009-04-30 |
| US20090111821A1 (en) | 2009-04-30 |
| TW200922585A (en) | 2009-06-01 |
| DOP2010000124A (es) | 2010-10-15 |
| AU2008317544A1 (en) | 2009-04-30 |
| NI201000072A (es) | 2011-03-24 |
| WO2009054794A1 (en) | 2009-04-30 |
| EA201000656A1 (ru) | 2010-12-30 |
| KR20100089091A (ko) | 2010-08-11 |
| EP2212316A4 (en) | 2012-06-27 |
| JP2011500798A (ja) | 2011-01-06 |
| CN101918399A (zh) | 2010-12-15 |
| MX2010004362A (es) | 2010-04-30 |
| IL205289A0 (en) | 2010-12-30 |
| CR11391A (es) | 2010-08-05 |
| EP2212316A1 (en) | 2010-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069030A1 (es) | Derivados de 1,2,4-triazol amino y de isoxazoles, composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento de trastornos gastrointestinales y del snc | |
| ES2715926T3 (es) | Compuestos para el tratamiento del cáncer | |
| JP2015510886A5 (es) | ||
| EA200602060A1 (ru) | Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
| AR107377A2 (es) | Compuestos derivados de tetrahidroquinolina | |
| EA200602058A1 (ru) | Производные адамантилпирролидин-2-она в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| AR094346A1 (es) | Derivados de azaindol como inhibidores de las proteína quinasas | |
| AR068846A1 (es) | Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer | |
| AR006906A1 (es) | Derivados de indazol sustituidos, composiciones farmaceuticas que los contienen, uso de los mismos e intermediarios de sintesis | |
| AR062965A1 (es) | Compuestos moduladores de receptores de glutamatometabotropicos mglur5, composiciones farmaceuticas que los contienen y usos terapeuticos en trastornos gastrointestinales, neurologicos y psiquiatricos agudos y cronicos | |
| CO5261634A1 (es) | Derivados de nicotinamida benzocondensada-heterociclico utiles como inhibidores selectivos de las isozimas pde4 | |
| WO2008087611A3 (en) | Pyrrolidine- and piperidine- bis-amide derivatives | |
| PT1261602E (pt) | Derivados imidazol-2-carboxamida como inibidores de cinase raf | |
| AR066020A1 (es) | Derivados de imidazolidin-2, 4-diona, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de parp-1. | |
| AR063804A1 (es) | Compuestos de azoniabiciclo[2.2.2]octano | |
| MY169179A (en) | Novel piperidine compound or salt thereof | |
| UA117151C2 (uk) | N-ациліміногетероциклічні сполуки | |
| HRP20080493T3 (hr) | Supstituirani kinolinski derivati kao mitotski inhibitori kinezina | |
| AR103566A1 (es) | Compuestos derivados de heteroarilo y heterociclo condensados | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| AR077301A1 (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano como antagonistas de 5-ht1a y 5-ht1b | |
| ATE480239T1 (de) | Angiogeneseinhibitoren | |
| ES2291958T3 (es) | Indazol-3-onas y analogos y derivados de las mismas que modulan la funcion del receptor vainilloide-1 (vr1). | |
| AR069028A1 (es) | Derivados de 1,2,4-triazol pirrolidina fusionados como moduladores de mglur5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |